$MDXG
MIMEDX GROUP, INC.

2013 Q4 Form 10-Q Financial Statement

#000137633913000010 Filed on November 08, 2013

View on sec.gov

Income Statement

Concept 2013 Q4 2013 Q3 2012 Q4
Revenue $17.99M $16.12M $10.51M
YoY Change 71.22% 102.62% 298.75%
Cost Of Revenue $3.110M $2.113M $1.690M
YoY Change 84.02% 48.28% 83.7%
Gross Profit $14.88M $14.00M $8.820M
YoY Change 68.74% 114.46% 413.05%
Gross Profit Margin 82.71% 86.88% 83.93%
Selling, General & Admin $14.28M $12.71M $8.150M
YoY Change 75.21% 120.81% 279.07%
% of Gross Profit 95.95% 90.78% 92.4%
Research & Development $1.380M $1.287M $1.140M
YoY Change 21.05% 53.5% 72.73%
% of Gross Profit 9.27% 9.19% 12.93%
Depreciation & Amortization $480.0K $185.0K $380.0K
YoY Change 26.32% -67.54% -17.39%
% of Gross Profit 3.23% 1.32% 4.31%
Operating Expenses $15.93M $14.00M $9.790M
YoY Change 62.72% 112.25% 135.9%
Operating Profit -$1.047M -$255.9K -$970.0K
YoY Change 7.94% -92.96% -60.1%
Interest Expense -$10.00K $4.527K -$630.0K
YoY Change -98.41% -96.89% 350.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$1.420M -$260.4K -$1.610M
YoY Change -11.8% -93.83% -37.6%
Income Tax $0.00 $46.70K $0.00
% Of Pretax Income
Net Earnings -$1.427M -$307.0K -$1.605M
YoY Change -11.09% -92.72% -37.72%
Net Earnings / Revenue -7.93% -1.9% -15.27%
Basic Earnings Per Share -$0.01 $0.00 -$0.01
Diluted Earnings Per Share -$0.01 $0.00 -$0.01
COMMON SHARES
Basic Shares Outstanding 97.85M shares 96.91M shares
Diluted Shares Outstanding 96.91M shares

Balance Sheet

Concept 2013 Q4 2013 Q3 2012 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $44.10M $6.100M $6.800M
YoY Change 548.53% -19.74% 65.85%
Cash & Equivalents $44.08M $6.062M $6.754M
Short-Term Investments
Other Short-Term Assets $1.300M $1.500M $700.0K
YoY Change 85.71% 200.0% 250.0%
Inventory $3.881M $4.533M $3.023M
Prepaid Expenses
Receivables $16.09M $13.71M $7.654M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $65.39M $25.85M $18.09M
YoY Change 261.49% 60.53% 162.16%
LONG-TERM ASSETS
Property, Plant & Equipment $4.086M $3.762M $1.072M
YoY Change 281.29% 276.16% 19.07%
Goodwill $4.040M $4.040M $4.040M
YoY Change -0.01%
Intangibles $11.18M $11.65M $11.91M
YoY Change -6.15% -21.06%
Long-Term Investments
YoY Change
Other Assets $0.00 $0.00 $70.00K
YoY Change -100.0% -100.0% -65.0%
Total Long-Term Assets $19.31M $19.45M $17.09M
YoY Change 12.94% 11.78% -15.38%
TOTAL ASSETS
Total Short-Term Assets $65.39M $25.85M $18.09M
Total Long-Term Assets $19.31M $19.45M $17.09M
Total Assets $84.69M $45.30M $35.18M
YoY Change 140.73% 35.21% 29.83%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.491M $2.206M $1.252M
YoY Change 98.97% -41.95% -16.55%
Accrued Expenses $1.406M $1.410M $990.7K
YoY Change 41.92% 23.84%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $9.608M $8.331M $5.017M
YoY Change 91.5% -20.65% 6.75%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $4.012M
YoY Change -100.0% -100.0% 48.61%
Other Long-Term Liabilities $1.518M $1.426M $353.3K
YoY Change 329.62% 375.49% -95.41%
Total Long-Term Liabilities $1.518M $1.426M $4.366M
YoY Change -65.23% -62.46% -58.02%
TOTAL LIABILITIES
Total Short-Term Liabilities $9.608M $8.331M $5.017M
Total Long-Term Liabilities $1.518M $1.426M $4.366M
Total Liabilities $11.13M $9.758M $15.18M
YoY Change -26.68% -32.24% -0.16%
SHAREHOLDERS EQUITY
Retained Earnings -$73.80M -$72.37M -$69.68M
YoY Change 5.9%
Common Stock $104.0K $97.69K $88.42K
YoY Change 17.62%
Preferred Stock
YoY Change
Treasury Stock (at cost) $25.00K $25.00K $25.00K
YoY Change 0.0%
Treasury Stock Shares 50.00K shares 50.00K shares 50.00K shares
Shareholders Equity $73.57M $35.54M $20.01M
YoY Change
Total Liabilities & Shareholders Equity $84.69M $45.30M $35.18M
YoY Change 140.73% 35.21% 29.83%

Cashflow Statement

Concept 2013 Q4 2013 Q3 2012 Q4
OPERATING ACTIVITIES
Net Income -$1.427M -$307.0K -$1.605M
YoY Change -11.09% -92.72% -37.72%
Depreciation, Depletion And Amortization $480.0K $185.0K $380.0K
YoY Change 26.32% -67.54% -17.39%
Cash From Operating Activities $830.0K $1.730M -$870.0K
YoY Change -195.4% -301.16% -47.27%
INVESTING ACTIVITIES
Capital Expenditures -$500.0K -$1.130M -$240.0K
YoY Change 108.33% 606.25% 242.86%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change -100.0%
Cash From Investing Activities -$500.0K -$1.130M -$240.0K
YoY Change 108.33% 606.25% -233.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 37.66M 1.280M 240.0K
YoY Change 15591.67% -78.63% -95.15%
NET CHANGE
Cash From Operating Activities 830.0K 1.730M -870.0K
Cash From Investing Activities -500.0K -1.130M -240.0K
Cash From Financing Activities 37.66M 1.280M 240.0K
Net Change In Cash 37.99M 1.880M -870.0K
YoY Change -4466.67% -62.17% -125.0%
FREE CASH FLOW
Cash From Operating Activities $830.0K $1.730M -$870.0K
Capital Expenditures -$500.0K -$1.130M -$240.0K
Free Cash Flow $1.330M $2.860M -$630.0K
YoY Change -311.11% -508.57% -60.13%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4155005 USD
CY2012Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1251684 USD
CY2013Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2205778 USD
CY2013Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
13706524 USD
CY2012Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
7653561 USD
CY2012Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
990697 USD
CY2013Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1410159 USD
CY2012Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2279840 USD
CY2013Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2694005 USD
CY2013Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
107834381 USD
CY2012Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
89627601 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1755669 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4155005 USD
CY2012Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
669469 USD
CY2013Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1667766 USD
CY2012Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
49000 USD
CY2013Q3 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
115000 USD
us-gaap Allowance For Doubtful Accounts Receivable Charge Offs
AllowanceForDoubtfulAccountsReceivableChargeOffs
33000 USD
us-gaap Allowance For Doubtful Accounts Receivable Charge Offs
AllowanceForDoubtfulAccountsReceivableChargeOffs
23000 USD
CY2013Q3 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
0 USD
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
1222290 USD
CY2012Q3 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
439064 USD
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
1328439 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1117646 USD
CY2012Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
449692 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
789809 USD
CY2013Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
259575 USD
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
22589158 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
17063212 shares
CY2013Q3 us-gaap Assets
Assets
45296293 USD
CY2012Q4 us-gaap Assets
Assets
35182608 USD
CY2013Q3 us-gaap Assets Current
AssetsCurrent
25845711 USD
CY2012Q4 us-gaap Assets Current
AssetsCurrent
18088791 USD
CY2007Q1 us-gaap Business Acquisition Contingent Consideration Potential Cash Payment
BusinessAcquisitionContingentConsiderationPotentialCashPayment
200000 USD
CY2008Q1 us-gaap Business Acquisition Contingent Consideration Shares Issuable
BusinessAcquisitionContingentConsiderationSharesIssuable
600000 shares
us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
107259 USD
us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
83016 USD
CY2013Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6061756 USD
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6754485 USD
CY2012Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7621226 USD
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4112326 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-692729 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
3508900 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-19213 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-70000 USD
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-1408 USD
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
132302 USD
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
382051 USD
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
913644 USD
CY2013Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0 USD
CY2012Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0 USD
CY2013Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2012Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2012Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
130000000 shares
CY2013Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
130000000 shares
CY2013Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
97686013 shares
CY2012Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
88423169 shares
CY2013Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
97636013 shares
CY2012Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
88373169 shares
CY2013Q3 us-gaap Common Stock Value
CommonStockValue
97686 USD
CY2012Q4 us-gaap Common Stock Value
CommonStockValue
88423 USD
CY2013Q3 us-gaap Contractual Obligation
ContractualObligation
6624284 USD
CY2013Q3 us-gaap Contractual Obligation Due After Fifth Year
ContractualObligationDueAfterFifthYear
478326 USD
CY2013Q3 us-gaap Contractual Obligation Due In Fifth Year
ContractualObligationDueInFifthYear
1410754 USD
CY2013Q3 us-gaap Contractual Obligation Due In Fourth Year
ContractualObligationDueInFourthYear
1369696 USD
CY2013Q3 us-gaap Contractual Obligation Due In Next Twelve Months
ContractualObligationDueInNextTwelveMonths
784771 USD
CY2013Q3 us-gaap Contractual Obligation Due In Second Year
ContractualObligationDueInSecondYear
1251301 USD
CY2013Q3 us-gaap Contractual Obligation Due In Third Year
ContractualObligationDueInThirdYear
1329436 USD
CY2013Q3 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
0 USD
CY2012Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
4012442 USD
us-gaap Cost Of Goods Sold
CostOfGoodsSold
3499117 USD
us-gaap Cost Of Goods Sold
CostOfGoodsSold
6216940 USD
CY2013Q3 us-gaap Cost Of Goods Sold
CostOfGoodsSold
2113438 USD
CY2012Q3 us-gaap Cost Of Goods Sold
CostOfGoodsSold
1425336 USD
CY2013Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
11438000 USD
CY2013Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
0 USD
CY2012Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
5313645 USD
us-gaap Debt Instrument Convertible Beneficial Conversion Feature
DebtInstrumentConvertibleBeneficialConversionFeature
0 USD
us-gaap Debt Instrument Convertible Beneficial Conversion Feature
DebtInstrumentConvertibleBeneficialConversionFeature
514456 USD
CY2013Q3 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.0500
CY2012Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
1301203 USD
CY2013Q3 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
0 USD
us-gaap Depreciation
Depreciation
354425 USD
us-gaap Depreciation
Depreciation
414165 USD
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.07
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.03
CY2013Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
0.00
CY2012Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.05
CY2012Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2753237 USD
CY2013Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4560380 USD
CY2012Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
4848756 USD
CY2013Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
5638565 USD
CY2013Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
1050998 USD
CY2013Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
263833 USD
CY2013Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
891753 USD
CY2013Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
981950 USD
CY2013Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
1028944 USD
CY2012Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
17526000 USD
CY2013Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
15811682 USD
CY2013Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
10173117 USD
CY2012Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
10878749 USD
us-gaap Gain Loss On Disposition Of Property
GainLossOnDispositionOfProperty
-8359 USD
us-gaap Gain Loss On Disposition Of Property
GainLossOnDispositionOfProperty
0 USD
CY2012Q4 us-gaap Goodwill
Goodwill
4040443 USD
CY2013Q3 us-gaap Goodwill
Goodwill
4040443 USD
CY2013Q3 us-gaap Gross Profit
GrossProfit
14002270 USD
us-gaap Gross Profit
GrossProfit
34970003 USD
CY2012Q3 us-gaap Gross Profit
GrossProfit
6528710 USD
us-gaap Gross Profit
GrossProfit
13044993 USD
CY2012Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-4219372 USD
CY2013Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-260418 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-6057092 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-2587940 USD
us-gaap Increase Decrease In Deferred Compensation
IncreaseDecreaseInDeferredCompensation
1807143 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
96975 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2013Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
46700 USD
CY2012Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
us-gaap Income Taxes Paid
IncomeTaxesPaid
96967 USD
us-gaap Income Taxes Paid
IncomeTaxesPaid
0 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
954094 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-39139 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
4278205 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
6052963 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
92986 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
419462 USD
us-gaap Increase Decrease In Deferred Compensation
IncreaseDecreaseInDeferredCompensation
1393016 USD
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
-41641 USD
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
312775 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1089733 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1510278 USD
CY2013Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
11648506 USD
CY2012Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
11911749 USD
us-gaap Interest Expense
InterestExpense
32503 USD
CY2013Q3 us-gaap Interest Expense
InterestExpense
4527 USD
us-gaap Interest Expense
InterestExpense
451196 USD
CY2012Q3 us-gaap Interest Expense
InterestExpense
145582 USD
us-gaap Interest Paid
InterestPaid
22971 USD
us-gaap Interest Paid
InterestPaid
8738 USD
CY2012Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1349121 USD
CY2013Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1422275 USD
CY2013Q3 us-gaap Inventory Gross
InventoryGross
4905794 USD
CY2012Q4 us-gaap Inventory Gross
InventoryGross
3181405 USD
CY2012Q4 us-gaap Inventory Net
InventoryNet
3022784 USD
CY2013Q3 us-gaap Inventory Net
InventoryNet
4533062 USD
CY2012Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
233747 USD
CY2013Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
206962 USD
CY2013Q3 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
372732 USD
CY2012Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
158621 USD
CY2013Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
3276557 USD
CY2012Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
1598537 USD
CY2013Q3 us-gaap Liabilities
Liabilities
9757863 USD
CY2012Q4 us-gaap Liabilities
Liabilities
15175306 USD
CY2013Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
45296293 USD
CY2012Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
35182608 USD
CY2012Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5070772 USD
CY2013Q3 us-gaap Liabilities Current
LiabilitiesCurrent
8331394 USD
CY2013Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
0 USD
CY2012Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
4012442 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6371877 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2966907 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-401864 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2534973 USD
CY2012Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2461113 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1124663 USD
CY2013Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1426469 USD
CY2012Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
299762 USD
us-gaap Payments For Repurchase Of Warrants
PaymentsForRepurchaseOfWarrants
0 USD
us-gaap Net Income Loss
NetIncomeLoss
-2684915 USD
CY2013Q3 us-gaap Net Income Loss
NetIncomeLoss
-307118 USD
CY2012Q3 us-gaap Net Income Loss
NetIncomeLoss
-4219372 USD
us-gaap Net Income Loss
NetIncomeLoss
-6057092 USD
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
us-gaap Operating Income Loss
OperatingIncomeLoss
-4383606 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-1226998 USD
CY2012Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3634726 USD
CY2013Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-255891 USD
CY2013Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
0 USD
CY2012Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
70000 USD
CY2013Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
155077 USD
CY2012Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
75154 USD
us-gaap Payments For Repurchase Of Warrants
PaymentsForRepurchaseOfWarrants
568 USD
us-gaap Payments For Tenant Improvements
PaymentsForTenantImprovements
0 USD
us-gaap Payments For Tenant Improvements
PaymentsForTenantImprovements
996866 USD
us-gaap Payments To Acquire Equipment On Lease
PaymentsToAcquireEquipmentOnLease
11002 USD
us-gaap Payments To Acquire Equipment On Lease
PaymentsToAcquireEquipmentOnLease
29797 USD
CY2007Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
100000 USD
us-gaap Payments To Acquire Machinery And Equipment
PaymentsToAcquireMachineryAndEquipment
401864 USD
us-gaap Payments To Acquire Machinery And Equipment
PaymentsToAcquireMachineryAndEquipment
2008407 USD
CY2013Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2012Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2012Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2013Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2012Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2013Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2012Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2013Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2013Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2012Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
657961 USD
CY2013Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1544369 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
885034 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1516580 USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
1480124 USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
5925539 USD
CY2012Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3351465 USD
CY2013Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
6455638 USD
CY2013Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3761633 USD
CY2012Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1071625 USD
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
99000 USD
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
119000 USD
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
0 USD
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
427126 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3458585 USD
CY2013Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1287361 USD
CY2012Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
838690 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1748847 USD
CY2012Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-69683722 USD
CY2013Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-72368637 USD
us-gaap Revenue Recognition Sales Returns Reserve For Sales Returns
RevenueRecognitionSalesReturnsReserveForSalesReturns
648000 USD
CY2013Q3 us-gaap Revenue Recognition Sales Returns Reserve For Sales Returns
RevenueRecognitionSalesReturnsReserveForSalesReturns
178000 USD
us-gaap Revenue Recognition Sales Returns Reserve For Sales Returns
RevenueRecognitionSalesReturnsReserveForSalesReturns
233000 USD
CY2012Q3 us-gaap Revenue Recognition Sales Returns Reserve For Sales Returns
RevenueRecognitionSalesReturnsReserveForSalesReturns
88000 USD
CY2012Q3 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
7954046 USD
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
16544110 USD
CY2013Q3 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
16115708 USD
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
41186943 USD
us-gaap Revenue Recognition Sales Of Goods
RevenueRecognitionSalesOfGoods
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Recognition</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company sells its products through a combination of a direct sales force and independent stocking distributors and representatives in the U.S. and independent distributors in international markets. The Company recognizes revenue when title to the goods transfers to customers, provided there are no material remaining performance obligations required of the Company or any matters of customer acceptance. In cases where the Company utilizes distributors or ships product directly to the end user, it recognizes revenue upon shipment provided all revenue recognition criteria have been met. A portion of the Company's revenue is generated from inventory maintained at hospitals or with the field representatives. For these products, revenue is recognized at the time the product has been used or implanted. The Company records estimated sales returns, discounts and allowances as a reduction of net sales in the same period revenue is recognized.&#160;&#160;The Company recorded approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$178,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$88,000</font><font style="font-family:inherit;font-size:10pt;"> for net sales returns provisions for the three months ended September 30, 2013 and 2012, respectively, and there were approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$153,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$135,000</font><font style="font-family:inherit;font-size:10pt;"> of charges against the related reserve during the three months ended September 30, 2013 and 2012, respectively. The Company recorded approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$648,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$233,000</font><font style="font-family:inherit;font-size:10pt;"> for net sales returns provisions for the nine months ended September 30, 2013 and 2012, respectively, and there were approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$485,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$161,000</font><font style="font-family:inherit;font-size:10pt;"> of charges against the related reserve during the nine months ended September 30, 2013 and 2012, respectively. </font></div></div>
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
14824937 shares
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
1.25
CY2013Q3 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
6482824 shares
CY2013Q3 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
15139543 shares
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
11443611 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
31948607 USD
CY2013Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
12711225 USD
CY2012Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
5756559 USD
us-gaap Share Based Compensation
ShareBasedCompensation
1755669 USD
us-gaap Share Based Compensation
ShareBasedCompensation
4155005 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0188
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0162
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0085
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0062
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
6000000 shares
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
22500000 shares
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
7182000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
179167 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
3.82
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3368000 shares
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.00
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
31918608 USD
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
15139543 shares
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
13614135 shares
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.28
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.42
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
31649823 USD
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
6482824 shares
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
2.25
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.94
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
1.11
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
5.19
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2013Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
18911451 USD
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P6Y7M6D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y10M24D
CY2013Q3 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
1.25
CY2013Q3 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
2.28
us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P7Y10M24D
CY2013Q3 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P7Y10M24D
CY2013Q3 us-gaap Treasury Stock Value
TreasuryStockValue
25000 USD
CY2013Q3 us-gaap Treasury Stock Shares
TreasuryStockShares
50000 shares
CY2012Q4 us-gaap Treasury Stock Value
TreasuryStockValue
25000 USD
us-gaap Stock Issued During Period Shares Acquisitions
StockIssuedDuringPeriodSharesAcquisitions
893267 shares
us-gaap Stock Issued During Period Shares Conversion Of Convertible Securities
StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
5272004 shares
CY2007Q1 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
1120000 shares
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
1610426 shares
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
5272004 USD
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
0 USD
CY2007Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
896000 USD
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1516580 USD
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
20007302 USD
CY2013Q3 us-gaap Stockholders Equity
StockholdersEquity
35538430 USD
CY2012Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
50000 shares
us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.&#160;</font></div></div>
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
CY2012Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
CY2013Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
95429988 shares
CY2012Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
84493164 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
84091014 shares
CY2013Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
96914856 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
95429988 shares
CY2013Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
96914856 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
84091014 shares
CY2012Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
84493164 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
95429988 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
84091014 shares
CY2012Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
84493164 shares
CY2013Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
96914856 shares
mdxg Cashless Exercise Of Warrants
CashlessExerciseOfWarrants
0 USD
mdxg Cashless Exercise Of Warrants
CashlessExerciseOfWarrants
167 USD
CY2008Q1 mdxg Contingent Payments To Licensor Shares Issued
ContingentPaymentsToLicensorSharesIssued
100000 shares
CY2007Q1 mdxg Contingent Royalty To Be Paid To Licensor
ContingentRoyaltyToBePaidToLicensor
0.03
CY2012Q4 mdxg Earnoutliabilitypayableinstock
Earnoutliabilitypayableinstock
5792330 USD
CY2013Q3 mdxg Earnoutliabilitypayableinstock
Earnoutliabilitypayableinstock
0 USD
mdxg Fair Value Adjustmentof Earn Out Liability
FairValueAdjustmentofEarnOutLiability
0 USD
CY2012Q3 mdxg Fair Value Adjustmentof Earn Out Liability
FairValueAdjustmentofEarnOutLiability
1320000 USD
mdxg Fair Value Adjustmentof Earn Out Liability
FairValueAdjustmentofEarnOutLiability
1320000 USD
CY2013Q3 mdxg Fair Value Adjustmentof Earn Out Liability
FairValueAdjustmentofEarnOutLiability
0 USD
CY2013Q3 mdxg Finite Lived And Infinite Lived Intangible Assets Accumulated Amortization
FiniteLivedAndInfiniteLivedIntangibleAssetsAccumulatedAmortization
5638565 USD
CY2012Q4 mdxg Finite Lived And Infinite Lived Intangible Assets Accumulated Amortization
FiniteLivedAndInfiniteLivedIntangibleAssetsAccumulatedAmortization
4848756 USD
CY2013Q3 mdxg Finite Lived And Infinite Lived Intangible Assets Gross
FiniteLivedAndInfiniteLivedIntangibleAssetsGross
16844682 USD
CY2012Q4 mdxg Finite Lived And Infinite Lived Intangible Assets Gross
FiniteLivedAndInfiniteLivedIntangibleAssetsGross
18559000 USD
CY2013Q3 mdxg Finite Lived Intangible Assets Amortization Expense After Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour
5955639 USD
CY2012Q4 mdxg Finite Lived Intangible Assets Impairment Adjustment
FiniteLivedIntangibleAssetsImpairmentAdjustment
1798495 USD
mdxg Impairmentof Intangible Assets
ImpairmentofIntangibleAssets
0 USD
CY2013Q3 mdxg Impairmentof Intangible Assets
ImpairmentofIntangibleAssets
0 USD
CY2012Q3 mdxg Impairmentof Intangible Assets
ImpairmentofIntangibleAssets
1798495 USD
mdxg Impairmentof Intangible Assets
ImpairmentofIntangibleAssets
1798495 USD
mdxg Increase Decreasein License Obligation
IncreaseDecreaseinLicenseObligation
0 USD
CY2012 mdxg Increase Decreasein License Obligation
IncreaseDecreaseinLicenseObligation
0 USD
CY2012Q4 mdxg Intangible Assets Impairment Adjustment
IntangibleAssetsImpairmentAdjustment
1798495 USD
CY2012Q4 mdxg Long Term Debt Including Related Party Current Maturities
LongTermDebtIncludingRelatedPartyCurrentMaturities
0 USD
CY2013Q3 mdxg Long Term Debt Including Related Party Current Maturities
LongTermDebtIncludingRelatedPartyCurrentMaturities
0 USD
CY2008Q1 mdxg Milestone Stock Issued During Period Value
MilestoneStockIssuedDuringPeriodValue
71000 USD
mdxg Noncash Stock Issued Acquisition
NoncashStockIssuedAcquisition
0 USD
mdxg Noncash Stock Issued Acquisition
NoncashStockIssuedAcquisition
893267 USD
CY2013Q3 mdxg Number Of Share Based Compensation Plans
NumberOfShareBasedCompensationPlans
3
CY2013Q3 mdxg Outstanding Assumed Options
OutstandingAssumedOptions
375000 shares
mdxg Paymentsfor Application Costs Patent
PaymentsforApplicationCostsPatent
0 USD
mdxg Paymentsfor Application Costs Patent
PaymentsforApplicationCostsPatent
526566 USD
CY2007Q1 mdxg Period Of Approval Maximum
PeriodOfApprovalMaximum
P30D
CY2012Q3 mdxg Provision Charges
ProvisionCharges
135000 USD
CY2013Q3 mdxg Provision Charges
ProvisionCharges
153000 USD
mdxg Provision Charges
ProvisionCharges
485000 USD
mdxg Provision Charges
ProvisionCharges
161000 USD
mdxg Share Based Compensation Arrangement By Share Based Payment Award Nonvested Options Outstanding Vested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedOptionsOutstandingVestedNumber
52999 shares
mdxg Stock Issued During Period Shares Accrued Director Fees
StockIssuedDuringPeriodSharesAccruedDirectorFees
167086 shares
mdxg Stock Issued During Period Shares Cashless Exercise
StockIssuedDuringPeriodSharesCashlessExercise
167183 shares
mdxg Stock Issued During Period Shares For Earn Out Liability
StockIssuedDuringPeriodSharesForEarnOutLiability
2632576 shares
mdxg Stock Issued During Period Shares For Earn Out Liability
StockIssuedDuringPeriodSharesForEarnOutLiability
1174915 shares
CY2008Q1 mdxg Stock Issued During Period Shares Issued For Purchase Of Surgical Sheets
StockIssuedDuringPeriodSharesIssuedForPurchaseOfSurgicalSheets
400000 shares
mdxg Stock Issued During Period Value Exercise Of Warrants
StockIssuedDuringPeriodValueExerciseOfWarrants
1480124 USD
mdxg Stock Issued During Period Value For Accrued Director Fees
StockIssuedDuringPeriodValueForAccruedDirectorFees
184653 USD
mdxg Stock Issued During Period Value For Accrued Director Fees
StockIssuedDuringPeriodValueForAccruedDirectorFees
0 USD
mdxg Stock Issued During Period Value For Earn Out Liability
StockIssuedDuringPeriodValueForEarnOutLiability
5792330 USD
mdxg Stock Issued During Period Value For Earn Out Liability
StockIssuedDuringPeriodValueForEarnOutLiability
3185223 USD
CY2008Q1 mdxg Stock Issued During Period Value Issued For Purchase Of Surgical Sheets
StockIssuedDuringPeriodValueIssuedForPurchaseOfSurgicalSheets
2596000 USD
CY2013Q3 mdxg Warrants Term
WarrantsTerm
P5Y
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2013
dei Document Period End Date
DocumentPeriodEndDate
2013-09-30
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0001376339
CY2013Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
97851013 shares
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Entity Registrant Name
EntityRegistrantName
MIMEDX GROUP, INC.
dei Entity Voluntary Filers
EntityVoluntaryFilers
No
dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No

Files In Submission

Name View Source Status
0001376339-13-000010-index-headers.html Edgar Link pending
0001376339-13-000010-index.html Edgar Link pending
0001376339-13-000010.txt Edgar Link pending
0001376339-13-000010-xbrl.zip Edgar Link pending
exhibit1056firstamendmentt.htm Edgar Link pending
exhibit1056firstamend_image1.jpg Edgar Link pending
exhibit1056firstamend_image4.jpg Edgar Link pending
exhibit1058mdxg-avkareamen.htm Edgar Link pending
exhibit311-certificationof.htm Edgar Link pending
exhibit312-certificationof.htm Edgar Link pending
exhibit321-certificationof.htm Edgar Link pending
exhibit322-certificationof.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
mdxg-20130930.xml Edgar Link completed
mdxg-20130930.xsd Edgar Link pending
mdxg-20130930x10xq.htm Edgar Link pending
mdxg-20130930_cal.xml Edgar Link unprocessable
mdxg-20130930_def.xml Edgar Link unprocessable
mdxg-20130930_lab.xml Edgar Link unprocessable
mdxg-20130930_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending